- Nanobiotix completed a sub-10% private placement by issuing new shares to US and EU institutional investors
- Proceeds will be used for the development of lead product NBTXR3 and preparation of its market access and launch
- Order book was of mainly long-only demand was covered by a majority of new institutional investors and institutional investors from the US
The investment services and investment institutions mentioned on the website may not be available in your jurisdiction or to anyone other than professional investors. More information about the countries where these investment institutions are registered and the persons to whom they may be offered can be found on the website.